Korro Presents Additional Preclinical Data For KRRO-110 At American Thoracic Society 2024 International Conference

5/20/24 2:33:01 PM ET

$KRRO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KRRO alert in real time by email

KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) mouse model
KRRO-110 showed 35µM of M-AAT one week post the first dose, with 0µM of M-AAT at baseline, increasing to 45µM of M-AAT at week 13

Get the next $KRRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KRRO

Date	Price Target	Rating	Analyst
10/21/2024	$153.00	Strong Buy	Raymond James
8/14/2024	$180.00	Outperform	William Blair
3/28/2024	$100.00 → $115.00	Buy	H.C. Wainwright
2/27/2024	$120.00	Outperform	BMO Capital Markets
12/4/2023	$100.00	Buy	H.C. Wainwright
11/29/2023	$70.00	Outperform	RBC Capital Mkts
11/10/2023	$180.00	Overweight	Piper Sandler

More analyst ratings

$KRRO
Press Releases

Fastest customizable press release news feed in the world

Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Tuesday, December 3, 2024, at 4:00 p.m. ET. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in 1x1 investor meetings at the conferenc
11/21/24 4:01:00 PM ET
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110 -First participant dosing anticipated in the first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2a study anticipated in 2026 CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that it has received approval from the Australian Bellberry Human Research Ethics Committee (HREC) and clearance from the A
11/21/24 7:30:00 AM ET
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care
Korro to Present at the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on the "Events & Presentations" page in the Investor section of Korro's website a
11/14/24 8:00:00 AM ET
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko
11/12/24 4:05:00 PM ET
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo
8/28/24 8:00:00 AM ET
$KRRO
$MRKR
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024 Further strengthened balance sheet with closing of $70.0 million private placement (PIPE) on April 22, 2024, with cash and cash equivalents of approximately $206 million at close Cash runway into second half of 2026 to fund anticipated interim readout of KRRO-110 in the second half of 2025 and FIH study completion in 2026 Appointed Kemi Olugemo, M.D., FANN as Chief Medical Officer CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company
5/14/24 4:01:00 PM ET
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care

Korro Presents Additional Preclinical Data For KRRO-110 At American Thoracic Society 2024 International Conference

Chat with this insight

Recent Analyst Ratings for $KRRO

$KRRO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Mathers Edward T bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

Florence Anthony A. Jr. bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

Yang Rick bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

$KRRO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

$KRRO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Agarwal Vineet exercised 800 shares at a strike of $11.68 and sold $56,000 worth of shares (800 units at $70.00) (SEC Form 4)

Chief Financial Officer Agarwal Vineet sold $799,527 worth of shares (10,216 units at $78.26) and exercised 10,216 shares at a strike of $11.99 (SEC Form 4)

SEC Form 4 filed by General Counsel Cerio Jeffrey

$KRRO SEC Filings

$KRRO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SEC Form 424B3 filed by Korro Bio Inc.

SEC Form 424B3 filed by Korro Bio Inc.

Korro Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Raymond James initiated coverage on Korro Bio with a new price target

William Blair initiated coverage on Korro Bio with a new price target

H.C. Wainwright reiterated coverage on Korro Bio with a new price target

$KRRO Press Releases

Fastest customizable press release news feed in the world

Korro to Participate in Upcoming Investor Conferences

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Korro to Present at the Jefferies London Healthcare Conference

$KRRO Market Insights

Live Market Insights

Korro Bio Joins Russell 2000, Russell 3000 And Russell Microcap Indexes

HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $100 Price Target

Korro Presents Additional Preclinical Data For KRRO-110 At American Thoracic Society 2024 International Conference

$KRRO Leadership Updates

Live Leadership Updates

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

Recent Analyst Ratings for
$KRRO

$KRRO
Insider Purchases

$KRRO
Large Ownership Changes

$KRRO
Insider Trading

$KRRO
SEC Filings

$KRRO
Analyst Ratings

$KRRO
Press Releases

$KRRO
Market Insights

$KRRO
Leadership Updates